Relapsed-Refractory Mature B-cell Non-Hodgkin Lymphoma in Children and Adolescents

Outcome of paediatric B-cell Non-Hodgkin Lymphoma (B-NHL) has significantly improved in the last decades due to risk adapted strategies and the addition of immunotherapy, (survival >90%). However, limited progress has been achieved in relapsed patients, mostly Burkitt lymphoma (<30%). Validation of prognostic biomarkers to identify candidates to novel therapies is imperative. This retrospective study reports on clinical and therapeutic data of 46 children and adolescents with relapsed B-NHL, including integrative molecular data of 16 (35%) cases. TP53 alterations were identified in 10 (60%) patients which were associated with worse outcome. Our data support the focus on TP53 as a potential biomarker.